Exciting news for younger adults at risk from RSV! The Food and Drug Administration (FDA) has expanded approval of Moderna’s RSV vaccine to include individuals aged 18 to 59. This announcement, made on June 12th by Moderna, significantly broadens access to protection against this common virus.

The vaccine was initially approved in 2024 for adults 60 and older. This latest expansion targets those aged 18-59 who have underlying health conditions that put them at higher risk of severe RSV illness. While RSV typically causes mild, cold-like symptoms, it can be dangerous for vulnerable populations.

Moderna’s CEO, Stéphane Bancel, celebrated the approval, highlighting its importance in protecting a wider segment of the population from serious RSV-related complications. He emphasized the serious health risks RSV poses to adults with chronic conditions.

The FDA has not yet issued an official statement. However, this expansion of vaccine eligibility represents a significant step forward in preventative healthcare and offers hope for those most vulnerable to the effects of RSV.